Radiation-Induced Breast Cancer: Long-Term Follow-up of Radiation Therapy for Benign Breast Disease

Context.—Atypical apocrine adenosis is a rare breast lesion in which the cellular population demonstrates cytologic alterations that may be confused with malignancy. The clinical significance and management of atypical apocrine adenosis are unclear because of the lack of long-term follow-up studies. Objective.—To determine the breast cancer risk in a retrospective series of patients with atypical apocrine adenosis diagnosed in otherwise benign, breast excisional biopsies. Design.—We identified 37 atypical apocrine adenosis cases in the Mayo Benign Breast Disease Cohort (9340 women) between 1967 and 1991 with a blinded pathology rereview. Breast cancer diagnoses subsequent to initial atypical apocrine adenosis biopsy were identified (average follow-up, 14 years). Results.—The mean age at diagnosis of atypical apocrine adenosis in the group was 59 years. Breast carcinoma subsequently developed in 3 women (8%) with atypical apocrine adenosis, diagnosed after follow-up intervals of 4, 12, and 18 years. The tumor from 1 of the 3 cases (33%) was ductal carcinoma in situ, contralateral to the original biopsy, and the other 2 cases (66%) were invasive carcinoma. Ages at the time of diagnosis of atypical apocrine adenosis were 55, 47, and 63 years for those that developed in situ or invasive carcinoma. Conclusions.—(1) Atypical apocrine adenosis was a rare lesion during the accrual era of our cohort (<1% of cases); (2) women found to have atypical apocrine adenosis were, on average, older than were other patients with benign breast disease, however, there does not seem to be an association with age and risk for developing carcinoma in patients diagnosed with atypical apocrine adenosis, as previously suggested; and (3) atypical apocrine adenosis does not appear to be an aggressive lesion and should not be regarded as a direct histologic precursor to breast carcinoma.

Download Full-text

Fatigue in patients with adjuvant radiation therapy for breast cancer: long-term follow-up

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-003-0540-9 ◽

2004 ◽

Vol 130 (6) ◽

pp. 327-333 ◽

Cited By ~ 59

Author(s):

Hans Geinitz ◽

Frank B. Zimmermann ◽

Reinhard Thamm ◽

Monika Keller ◽

Raymonde Busch ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Adjuvant Radiation ◽

Adjuvant Radiation Therapy ◽

Long Term Follow Up

Download Full-text

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Journal of Clinical Oncology ◽

10.1200/jco.2012.45.2615 ◽

2013 ◽

Vol 31 (19) ◽

pp. 2382-2387 ◽

Cited By ~ 527

Author(s):

Kevin S. Hughes ◽

Lauren A. Schnaper ◽

Jennifer R. Bellon ◽

Constance T. Cirrincione ◽

Donald A. Berry ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Distant Metastasis ◽

Early Stage ◽

Breast Cancer Specific Survival ◽

Cancer Specific Survival ◽

Er Positive ◽

Long Term Follow Up

Purpose To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Patients and Methods Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) –positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer–specific survival, time to distant metastasis, and overall survival (OS). Results Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer–specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively. Conclusion With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.

Download Full-text

Radiation-Induced Sarcoma following Curative Radiotherapy for Testicular Seminoma: Case Report and Brief Review of the Literature

Tumori Journal ◽

10.1177/030089169708300320 ◽

1997 ◽

Vol 83 (3) ◽

pp. 721-723 ◽

Cited By ~ 5

Author(s):

Moshe E. Stein ◽

Michelle Leviov ◽

Keren Drumea ◽

Ludmilla Goralnik ◽

Innes Miselevich ◽

...

Keyword(s):

Radiation Therapy ◽

Absolute Number ◽

Review Of The Literature ◽

Testicular Seminoma ◽

Muscle Tissues ◽

Curative Radiotherapy ◽

Long Term Follow Up ◽

Radiation Induced

We report a case of radiation-induced retroperitoneal leiomyosarcoma which developed 37 years after the patient received radiation therapy for testicular seminoma. The sarcoma originated within the para-aortic field, extensively involving neighboring organs, soft tissue and muscle tissues, and could be only partially resected. The absolute number of these secondary sarcomas is low, but the risk of developing such neoplasms calls for awareness in the long-term follow-up of cured seminoma patients.

Download Full-text